AAA
SPRB

Affinity Asset Advisors’s Spruce Biosciences SPRB Stock Holding History

Affinity Asset Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
+30,000
New +$1.68M 0.07% 101

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Affinity Asset Advisors's SPRB Position: Q2 2026 in Review

Affinity Asset Advisors opened a new position in Spruce Biosciences (SPRB) in Q2 2026: 30,000 shares worth $1.62M. The stake represents 0.07% of the portfolio and ranks #101 among its holdings.

35 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Affinity Asset Advisors held 30,000 shares of Spruce Biosciences worth $1.62M as of Q2 2026.
  • Spruce Biosciences was a new Affinity Asset Advisors position in Q2 2026.
  • Spruce Biosciences made up 0.07% of Affinity Asset Advisors's portfolio in Q2 2026, its #101 holding.
  • 35 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.